PubMed:12912965
Annnotations
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 237-258 | gene:7124 | denotes | tumor necrosis factor |
| T1 | 324-361 | disease:C1168401 | denotes | head and neck squamous cell carcinoma |
| R1 | T0 | T1 | associated_with | tumor necrosis factor,head and neck squamous cell carcinoma |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 12912965-1#79#100#gene7124 | 237-258 | gene7124 | denotes | tumor necrosis factor |
| 12912965-1#166#203#diseaseC1168401 | 324-361 | diseaseC1168401 | denotes | head and neck squamous cell carcinoma |
| 79#100#gene7124166#203#diseaseC1168401 | 12912965-1#79#100#gene7124 | 12912965-1#166#203#diseaseC1168401 | associated_with | tumor necrosis factor,head and neck squamous cell carcinoma |
PubMed_Structured_Abstracts
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 158-460 | OBJECTIVE | denotes | The purpose of this study was to examine the effect of combined treatment with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and cisplatin in human head and neck squamous cell carcinoma. HNSCC-6 cells were treated with 0.1-1 micro g/ml TRAIL and/or 1-10 micro g/ml cisplatin for 24 h. |
| T2 | 470-1480 | RESULTS | denotes | TRAIL alone or cisplatin alone caused minimal cytotoxicity. The combination of TRAIL and cisplatin synergistically enhanced apoptotic death, caspase-8 and caspase-3 activation, as well as poly(ADP-ribose) polymerase cleavage. However, the total cellular levels and the surface expression of TRAIL receptor proteins, such as death receptors 4 and 5 and decoy receptors 2 and 1, were not significantly changed by treatment with TRAIL and cisplatin. Interestingly, the level of the short form of Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein (FLIP(S)) but not the long form of Fas-associated death domain-like interleukin-1beta-converting enzyme-inhibitory protein was reduced through cleavage. Benzyloxycarbonyl-Asp-Glu-Val-Asp-fluoromethylketone a caspase-3 inhibitor, blocked the cleavage of FLIP(S) and caspase-3 activation. Overexpression of FLIP(S) protected cells from apoptotic death and FLIP(S) cleavage during treatment with TRAIL in combination with cisplatin. |
| T3 | 1494-1661 | CONCLUSIONS | denotes | These results suggest that caspase-3 is responsible for FLIP(S) cleavage, and the cleavage of FLIP(S) is one of facilitating factors for TRAIL-induced apoptotic death. |